FindTrial
Sign In

The prospective study of focal high-dose rate brachytherapy for primary clinically localized prostate cancer

The prospective study of focal high-dose rate brachytherapy for primary clinically localized prostate cancer - The prospective study of focal high-dose rate brachytherapy for primary clinically localized prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000040121
Enrollment
12
Registered
2020-04-15
Start date
2020-04-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Focal high-dose rate brachytherapy for Prostate using Irisium

Sponsors

Kawasaki Medical School Hospita, Department of Urology
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1.Only single region prostate cancer revealed same region, that suspcet of clinically significant cancer by mpMRI prior biopsy 2.Prostate cancer diagnosed pathological examination 3.Proatate cancer of Gleason score 3+3 or 3+4 4.Not ever accepte the therapy for prostate cancer 5.No metastasis region by radiological examination 6.PSA value less than 20ng/ml 7.Performance Status is 0, 1 or2

Exclusion criteria

Exclusion criteria: 1.Prostate cancer region close to rectal wall 2.multiple cancer region diagnosed by prostate biopsy 3.Medical history for radiation therapy of the pelvis 4.Unfit for regularly MRI examination for follow-up 5.Administration of glucocorticoid or 5-arufa reductase 6.Actively double cancer

Design outcomes

Primary

MeasureTime frame
1.The safety for focal high-dose rate brachytherapy using Irisium for clinically localized prostate cancer 2.The efficacy for pathological evaluation of re-biopsy of focal radiation region—

Countries

Japan

Contacts

Public ContactYoshiyuki Miyaji

Kawasaki Medical School Hospital Urology

miyaji@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026